Amgen
New Guidance for Managing DOAC-Related Bleeding
Anew resource from the Anticoagulation Forum provides guidance on bleeding related to DOACs, highlighting areas ...
MAY 24, 2021
FDA Approves Evenity for Postmenopausal Women at High Risk for Fracture
About 10 million people in the United States have osteoporosis.
APRIL 10, 2019
FDA Approves Nivestym, Second Biosimilar of Neupogen
The FDA approved Pfizer's Nivestym, a biosimilar of Neupogen for all eligible indications as the reference ...
JULY 23, 2018
FDA Approves Fulphila, First Biosimilar to Neulasta
Mylan's Fulphila is the first biosimilar to Neulasta to decrease the chance of infection as suggested by febrile ...
JUNE 4, 2018
FDA Grants New Indication for Prolia to Treat Glucocorticoid-Induced Osteoporosis
Prolia received a new indication from the FDA to treat glucocorticoid-induced osteoporosis in adults at high risk ...
MAY 23, 2018
A Paradigm Shift In Managing Migraines
At Asembia 2018, SPC Editorial Director David Bronstein sat down with Dawn C. Buse, PhD, a clinical professor at ...
MAY 18, 2018
Aimovig Gets FDA Nod for Migraine Prevention
Aimovig is the first FDA-approved treatment to block the calcitonin gene–related peptide receptor, which ...
MAY 18, 2018
First Epoetin alfa Biosimilar Receives FDA Approval for Anemia
Retacrit is the first U.S. biosimilar erythropoiesis-stimulating agent (ESA). Although not listed as an ...
MAY 15, 2018
Abarca, Amgen Bet on PCSK9 Outcomes
Innovative pharmacy benefits manager (PBM) Abarca has entered into an outcomes-based contract for the proprotein ...
APRIL 11, 2018
FDA Expands Approval of Blincyto for Certain ALL Patients at Risk for Relapse
Blincyto is the first and only FDA-approved therapy for minimal residual ALL.
MARCH 29, 2018
PBM Abarca Announces Outcomes-Based Contract for Amgen’s Evolocumab
Innovative PBM Abarca has entered into an outcomes-based contract for the PCSK9 inhibitor evolocumab with Amgen, ...
MARCH 9, 2018
New Indication Granted for Repatha for Wider Group of Patients: Adults with CVD
Repatha's indication had been limited to patients with homozygous familial hypercholesterolemia who require ...
DECEMBER 2, 2017
